Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Cybrexa Doses First Patient in Peptide-Drug Conjugate Trial For Ovarian Cancer
Details : CBX-12 is a PDC that utilizes Cybrexa’s alphalex technology to enhance delivery of exatecan to tumor cells and is composed of a pHLIP. It is being evaluated for platinum-resistant ovarian cancer.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
July 10, 2024
A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 18, 2024
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBX-12 is a PDC that includes the highly potent topoisomerase I inhibitor exatecan. CBX-12 demonstrated safety and tolerability, without significant gastrointestinal toxicity.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
October 28, 2022
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : HighCape Capital
Deal Size : $25.0 million
Deal Type : Series B Financing
Cybrexa Therapeutics Closes $25 Million Series B Financing
Details : Proceeds from the financing will be used to support the planned advancement of Cybrexa’s lead candidate CBX-12 (alphalex™-exatecan) into the clinic. The first patient dosing in the Phase 1 study is expected in the first half of 2021.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
October 03, 2021
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : HighCape Capital
Deal Size : $25.0 million
Deal Type : Series B Financing
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Study evaluating the efficacy of CBX-12 (alphalex™-exatecan) in combination with PD-1- and CTLA4-targeted immune checkpoint inhibitors in preclinical cancer models. CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomeras...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
September 28, 2021
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cybrexa Therapeutics to Present at BTIG Virtual Biotechnology Conference 2021
Details : CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 08, 2021
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CBX-12 is a novel treatment for solid tumors that includes a highly potent topoisomerase I inhibitor payload that is in the same class as the payloads used by antibody-drug conjugates (ADCs) ENHERTU® and TRODELVY™.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
March 22, 2021
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Details : Cybrexa and NCI to collaborate on clinical development of Cybrexa’s lead candidate, CBX-12, to assess the safety and efficacy in oncology patients with solid tumors.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
February 24, 2021
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : National Institutes of Health
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the GLP toxicology studies CBX-12 was delivered via IV infusion, and based on multiple parameters, including mortality, clinical observations, body weights and food consumption, the results established a significant therapeutic index of ~20X over exat...
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
January 28, 2021
Lead Product(s) : CBX-12
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable